⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Impact Therapeutics, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Impact Therapeutics, Inc.
↗Shanghai, China
Impact Therapeutics is a commercial-stage biotechnology company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. The company has established a comprehensive DNA damage response (DDR) pipeline and is expanding into emerging modalities including dual-payload antibody-drug conjugates (ADCs) and protein degraders.
Founded in 2009 and headquartered in Shanghai, China, the company focuses on addressing unmet medical needs in oncology. Its core product, Senaparib (a PARP1/2 inhibitor), has been commercialized in China for ovarian cancer maintenance therapy. The company is publicly traded on the Hong Kong Stock Exchange (HKEX: 7630).
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$5M-$10M
Founded:2009
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$180M
Investors:Lilly Asia Ventures, Tencent, Junshi Biosciences, WuXi AppTec, Decheng Capital, Dingxin Capital
STOCK
Exchange:Hong Kong Stock Exchange
Ticker:7630.HK
Market Cap:$1.41B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, ADC, Protein degrader
Active Trials:22
Trial Phases:Phase 1: 4 | Phase 2: 2 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Huadong Medicine (Commercialization), Junshi Biosciences (Joint Venture), Eikon Therapeutics (Collaboration)
COMPETITION
Position:Emerging
Competitors:Jazz Pharmaceuticals, Sana Biotechnology, Kite Pharma
LEADERSHIP
Key Executives:
Sui-Xiong Cai - CEO & Executive Director
Ye Tian - Executive VP, CSO & Executive Director
Board Members:Cong Xu, Ning Ma, Tao Liu, Qiang Xu
LINKS
Website:impacttherapeutics.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Impact Therapeutics, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.